Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Surufatinib in Advanced Well-Differentiated Neuroendocrine Tumors: A Multicenter, Single-Arm, Open-Label, Phase Ib/II Trial
Jian-Ming Xu, Jie Li, Chunmei Bai, et al.
Clinical Cancer Research (2019) Vol. 25, Iss. 12, pp. 3486-3494
Open Access | Times Cited: 67

Showing 1-25 of 67 citing articles:

Molecular principles of metastasis: a hallmark of cancer revisited
Jawad Fares, Mohamad Y. Fares, Hussein H. Khachfe, et al.
Signal Transduction and Targeted Therapy (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 1808
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Lei Zhong, Yueshan Li, Liang Xiong, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 1164
Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study
Jianming Xu, Lin Shen, Zhiwei Zhou, et al.
The Lancet Oncology (2020) Vol. 21, Iss. 11, pp. 1500-1512
Closed Access | Times Cited: 151
European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for colorectal neuroendocrine tumours
Anja Rinke, Valentina Ambrosini, Clarisse Dromain, et al.
Journal of Neuroendocrinology (2023) Vol. 35, Iss. 6
Open Access | Times Cited: 69
New clinical trial design in precision medicine: discovery, development and direction
Xiao-Peng Duan, Bao‐Dong Qin, Xiao‐Dong Jiao, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 57
Pancreatic neuroendocrine tumors: A review of serum biomarkers, staging, and management
Zuyi Ma, Yuanfeng Gong, Hongkai Zhuang, et al.
World Journal of Gastroenterology (2020) Vol. 26, Iss. 19, pp. 2305-2322
Open Access | Times Cited: 137
Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study
Jianming Xu, Lin Shen, Chunmei Bai, et al.
The Lancet Oncology (2020) Vol. 21, Iss. 11, pp. 1489-1499
Closed Access | Times Cited: 137
Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509)
Jaume Capdevila, Nicola Fazio, Carlos López, et al.
Journal of Clinical Oncology (2021) Vol. 39, Iss. 20, pp. 2304-2312
Open Access | Times Cited: 81
Treatment Options for Pancreatic Neuroendocrine Tumors
Amit Akirov, Vincent Larouche, Sameerah Alshehri, et al.
Cancers (2019) Vol. 11, Iss. 6, pp. 828-828
Open Access | Times Cited: 70
The State-of-the-Art of Phase II/III Clinical Trials for Targeted Pancreatic Cancer Therapies
Andrés García-Sampedro, Gabriella Gaggia, Alexander Ney, et al.
Journal of Clinical Medicine (2021) Vol. 10, Iss. 4, pp. 566-566
Open Access | Times Cited: 34
Incidence and survival of neuroendocrine neoplasms in China with comparison to the United States
Rongshou Zheng, Hong Zhao, Lan An, et al.
Chinese Medical Journal (2023)
Open Access | Times Cited: 14
Epidemiologic trends of and factors associated with overall survival in patients with neuroendocrine tumors over the last two decades in the USA
Peiwen Wu, Dongjie He, Hao Chang, et al.
Endocrine Connections (2023) Vol. 12, Iss. 12
Open Access | Times Cited: 14
Structural basis and selectivity of sulfatinib binding to FGFR and CSF-1R
Qianmeng Lin, Shuyan Dai, Lingzhi Qu, et al.
Communications Chemistry (2024) Vol. 7, Iss. 1
Open Access | Times Cited: 6
The stromal microenvironment endows pancreatic neuroendocrine tumors with spatially specific invasive and metastatic phenotypes
Ye Zeng, Qiang Li, Yuheng Hu, et al.
Cancer Letters (2024) Vol. 588, pp. 216769-216769
Closed Access | Times Cited: 5
Targeting tumor-associated macrophages to reverse antitumor drug resistance
Li Sheng, Jiyao Sheng, Dan Zhang, et al.
Aging (2024) Vol. 16, Iss. 11, pp. 10165-10196
Open Access | Times Cited: 5
Systemic treatment of hepatocellular carcinoma: from sorafenib to combination therapies
Christoph Roderburg, Burcin Özdirik, Alexander Wree, et al.
Hepatic Oncology (2020) Vol. 7, Iss. 2
Open Access | Times Cited: 35
Molecular Pathology of Well-Differentiated Gastro-entero-pancreatic Neuroendocrine Tumors
L. Sylvia, Stefano La Rosa, Olca Baştürk, et al.
Endocrine Pathology (2021) Vol. 32, Iss. 1, pp. 169-191
Closed Access | Times Cited: 30
Treatment of advanced gastroenteropancreatic neuroendocrine neoplasia, are we on the way to personalised medicine?
Anja Rinke, Christoph J. Auernhammer, Lisa Bodei, et al.
Gut (2021) Vol. 70, Iss. 9, pp. 1768-1781
Closed Access | Times Cited: 30
Surufatinib: First Approval
Yahiya Y. Syed
Drugs (2021) Vol. 81, Iss. 6, pp. 727-732
Closed Access | Times Cited: 30
Targeted Cancer Therapy: What’s New in the Field of Neuroendocrine Neoplasms?
Anna La Salvia, Paula Espinosa-Olarte, María Carmen Riesco Martínez, et al.
Cancers (2021) Vol. 13, Iss. 7, pp. 1701-1701
Open Access | Times Cited: 28
Novel therapeutics for patients with well-differentiated gastroenteropancreatic neuroendocrine tumors
Satya Das, Arvind Dasari
Therapeutic Advances in Medical Oncology (2021) Vol. 13
Open Access | Times Cited: 28
Surufatinib plus toripalimab in patients with advanced solid tumors: a single-arm, open-label, phase 1 trial
Yanshuo Cao, Ming Lu, Yu Sun, et al.
Journal of Cancer Research and Clinical Oncology (2022) Vol. 149, Iss. 2, pp. 779-789
Open Access | Times Cited: 20
Surufatinib in Chinese Patients with Locally Advanced or Metastatic Differentiated Thyroid Cancer and Medullary Thyroid Cancer: A Multicenter, Open-Label, Phase II Trial
Jiaying Chen, Qinghai Ji, Chunmei Bai, et al.
Thyroid (2020) Vol. 30, Iss. 9, pp. 1245-1253
Closed Access | Times Cited: 31
Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors
Mauro Cives, Eleonora Pellè, Jonathan Strosberg
Journal of Clinical Medicine (2020) Vol. 9, Iss. 11, pp. 3655-3655
Open Access | Times Cited: 30
From Liver Cirrhosis to Cancer: The Role of Micro-RNAs in Hepatocarcinogenesis
Raphael Mohr, Burcin Özdirik, Joeri Lambrecht, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 3, pp. 1492-1492
Open Access | Times Cited: 25
Page 1 - Next Page

Scroll to top